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Introduction: The TuberOus SClerosis registry to increase disease Awareness (TOSCA)
is an international disease registry designed to provide insights into the clinical
characteristics of patients with Tuberous Sclerosis Complex (TSC). The aims of this study
were to identify issues that arose during the design, execution, and publication phases
of TOSCA, and to reflect on lessons learnt that may guide future registries in rare and
complex diseases.
Methods: A questionnaire was designed to identify the strengths, weaknesses, and
issues that arose at any stage of development and implementation of the TOSCA registry.
The questionnaire contained 225 questions distributed in 7 sections (identification of
issues during registry planning, during the operation of the registry, during data analysis,
during the publication of the results, other issues, assessment of lessons learnt, and
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additional comments), and was sent by e-mail to 511 people involved in the registry,
including 28 members of the Scientific Advisory Board (SAB), 162 principal investigators
(PIs), and 321 employees of the sponsor belonging to the medical department or that
were clinical research associate (CRA). Questionnaires received within the 2 months from
the initial mailing were included in the analysis.
Results: A total of 53 (10.4%) questionnaires were received (64.3% for SAB members,
12.3% for PIs and 4.7% for employees of the sponsor), and the overall completeness rate
for closed questions was 87.6%. The most common issues identified were the limited
duration of the registry (38%) and issues related to handling of missing data (32%). In
addition, 25% of the respondents commented that biases might have compromised
the validity of the results. More than 80% of the respondents reported that the registry
improved the knowledge on the natural history and manifestations of TSC, increased
disease awareness and helped to identify relevant information for clinical research in TSC.
Conclusions: This analysis shows the importance of registries as a powerful tool to
increase disease awareness, to produce real-world evidence, and to generate questions
for future research. However, there is a need to implement strategies to ensure patient
retention and long-term sustainability of patient registries, to improve data quality, and to
reduce biases.
Keywords: lessons, issues, strengths, weaknesses, TOSCA, registry, TSC
INTRODUCTION
Patient registries are organized systems that use observational
study methods to collect uniform data on a patient population
defined by a particular disease, exposure or condition (e.g., age,
pregnancy, specific patient characteristics), and which is followed
over time (1). Patient registries may also help to understand
the natural history of the disease, to estimate the human and
economic burden of the disease, to monitor clinical practice
patterns, to identify patients’ subgroups that might be included in
future clinical trials and to generate new research questions (2).
Therefore, patient registries are a key instrument to develop
clinical research, and to improve patient care and healthcare
planning, particularly in the field of rare diseases. In spite of its
usefulness, patient registries do have several limitations arising
from biases, lack of standardization in data collection, accuracy,
and comprehensiveness of the data, fragmentation of clinical
data, and ethical concerns (2). Most registries are carried out in
a small number of centers belonging to a single country or, at
best, in a limited number of countries (3), which constitutes an
important limitation for the generalizability of the results. The
fact that many registries are initiated in the field of academia
might also limit their use for pharmaceutical research. In addition
to academic initiatives on registries, there are different initiatives
worldwide for patients’ group registries where the accuracy of the
data can be questioned.
The TuberOus SClerosis registry to increase disease
Awareness (TOSCA) is a multicenter, international disease
registry that was designed to assess manifestations, interventions,
and outcomes in patients with Tuberous Sclerosis Complex
(TSC), a rare genetic disorder characterized by growth of
hamartomas in several organs (4). This registry, designed as an
observational clinical study, enrolled from 2012 to 2014 a total of
2,216 patients in 170 sites in 31 countries worldwide. Patients of
any age diagnosed with TSC having a documented visit for TSC
within the preceding 12 months or newly diagnosed patients
(4) were enrolled after signing an inform consent form (ICF)
approved by local ethic committee (EC)/institutional review
board (IRB). Patients’ data were collected at baseline visit and at
5 yearly follow-up visits and recorded by principal investigators
(PIs) in an electronic clinical database. The registry clinical
database lock occurred in 2017.
The TOSCA registry design consisted of a main “core” part
and a number of sub-studies (referred to as “research projects”
or “petal projects”) (4). The “core” section was designed to
collect a general predefined set of patient background data
including demographics, family history, prenatal history, and
disease features (i.e., neurological, neuropsychiatric, renal,
cardiovascular, pulmonary). Additional and more detailed data
related to specific disease manifestations were collected in
the sub-studies/research projects of the registry. Additionally,
the TOSCA registry included a sub-study designed as post
approval safety study (PASS), following the European Medicines
Agency’s (EMA) request (EMEA/H/C/002311/II/0004), to
document the long-term safety and tolerability profile
of Votubia R© in the treatment of TSC patients residing
in the European Union for the licensed indications and
collect everolimus therapeutic drug monitoring (TDM) data
within routine clinical practice as per SmPC. Clinical study
protocol and final study results are available on ENCePP
portal at http://www.encepp.eu/ (EU PAS Register Number
EUPAS324) (5).
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The TOSCA registry was funded, designed and managed
by a pharmaceutical sponsor (Novartis) with the support of a
Scientific Advisory Board (SAB), a Working Committee (WC),
and Research Groups (4):
• The SAB consisted of up to 30 members, including
TSC healthcare professionals, patient representatives and a
maximum of three representatives of the sponsor (Novartis).
The medical experts were selected based on the number
of publications in TSC, research interests and working in
reference sites for TSC in their country. Patient representatives
were included as well to ensure that their perspective is
considered in the project design and execution. The chair
and co-chair were selected by vote of all members. The SAB
was responsible for the scientific principles of the registry, the
promotion of the use of the registry, the publication of data,
and the approval of research projects. All the details of SAB
constitution, rules and goals are reported in a SAB charter.
• The WC was a subgroup consisting of up to 14 members
from the SAB and was responsible for the registry content
and coordination of all the operational activities, for defining
the statistical analysis plan and publication policy, and for
developing and maintaining the database structure of the
registry. All the details of WC constitution, rules, and goals
were reported in a WC charter.
• Research groups were made up of physicians participating
in the registry and their role consists on the submission
of research project proposals to the WC, together with the
subsequent management of that particular project.
Apart from being the largest registry in patients with TSC,
the TOSCA registry has noteworthy features, including its
worldwide scope (including European and non-European
countries), its nature as a large-scale cooperation effort
between healthcare professionals, patient representatives and
pharmaceutical industry, the inclusion of a large number of
patients, the design as a core minimal set of data and the more
detailed data collection on specific aspects (research projects),
the long-term follow-up (up to 5 years), and the inclusion of a
PASS sub-study (4). For this reason, both in terms of contents
and structure, the TOSCA registry offers an excellent opportunity
to assess what lesson can be learnt from a registry, which issues
should be addressed andwhat pitfalls can be avoidedwhen setting
up and managing an international registry in a rare disease.
OBJECTIVE
The aim of this analysis was 2-fold: firstly, to identify issues that
arose during the design and operation of the TOSCA registry and
during the interpretation and publication of the results; secondly,
it aimed to identify areas for improvement and pitfalls that can be
useful for the development of successful future registries in rare
and complex diseases.
This paper is structured as follows. Section Methods describes
the methodology and the instruments employed to extract the
information. Section Results describes the issues encountered by
each group of stakeholders in every domain of the registry; it also
outlines the pitfalls and lessons learnt from the integration of the
research projects and the everolimus sub-study PASS within the
TOSCA registry. Finally, sectionDiscussion contains a discussion
of the results and provides recommendations for future registries
in rare, multisystemic, and complex diseases.
METHODS
A questionnaire was designed to identify issues that might
have arisen at any stage of the TOSCA registry project from
its inception to the publication of the results, and to identify
its strengths and weakness, and opportunities and threats that
could be of interest for the development of future registries
in rare diseases. It was developed by the TOSCA clinical
trial head with contribution of TOSCA patient representatives
steering committee members and Novartis quantitative safety
and epidemiology department. The questionnaire was built
following a guide aimed to support the design, implementation,
analysis, interpretation, and quality evaluation of registries
published by Gliklich et al. (2). The questions included were
prepared based on the steps to conduct a registry described in this
guideline and the specific TOSCA registry project characteristics.
The questionnaire contained 225 questions split into seven
sections (Supplementary Material); the first five sections
covered a range of aspects related to issues during the registry
(planning, operation, data analysis, results publication, and
other issues), and the last two were devoted to assess lessons
learnt from the TOSCA registry and to gather additional
comments (Table 1).
On September 7th 2018 the questionnaire was sent by e-mail
to the 511 people who had been involved in the TOSCA registry.
Twenty-eight of them were part of the SAB, while 162 were
principal investigators (PIs) and 321 were Novartis employees
not included in the SAB. All the receptors of the questionnaire
(henceforth “participants”) received the same document, but
some questions precluded respondents to answer subsequent
parts of the questionnaire (for instance, if participants responded
that were not involved in budget planning, allocation and/or
control, they were invited to skip the subsequent questions
regarding these topics). To facilitate the analysis, most questions
were close-ended (“yes”/“no” or using a Likert scale). Besides,
all the questions contained “N/A” (not applicable) option and a
free-text field where the participants were encouraged to justify
their answers. The participants were given 2 months for replying
and two reminders were sent. No remuneration was offered
to respondents.
The analysis was carried out on the completed questionnaires
received in the 2 months following the initial mailing
(cut-off date: November 8th 2018). All data were analyzed
using Microsoft Excel. Relative and absolute frequencies were
analyzed for all the questions, and whenever possible, for
the groups of questions belonging to the same section
or subsection.
RESULTS
By the cut-off date (November 8th 2018), a total of 53
questionnaires were received (53/511; 10.4%). The response
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TABLE 1 | Structure of the Questionnaire.
1) Identification of issues during registry planning
• Perception on the definition of the purpose and the objectives of the
registry
• Perception on the definition of the inclusion/exclusion criteria
• Definition of the variables included in the registry
• Definition of the size, the duration, the setting and the geographical areas
• Identification of stakeholders, team building and establishment of a
governance
• Data access & use of data
• Publication plan
• Development of the protocol and related documents
• Development of the project plan
• Development of risk management plans & risk management during the
registry
2) Identification of issues during the operation of the registry
• Issues related to patient recruitment or retention
◦ Barriers to patient recruitment/retention
◦ Evaluation of success of patient recruitment strategies
◦ Evaluation of success of patient retention strategies
◦ Evaluation of center/physician or patient selection bias
• Issues related to data collection & quality assurance
◦ Issues related to data collection
◦ Identification of quality issues & timing for detection
• Issues related to budget
• Issues related to project management
◦ Ownership & accountability
◦ Coordination
◦ Estimation of the use of resources/duration/complexity
3) Issues during data analysis
• Identification of sources of bias
• Treatment of missing data
• Appropriateness of time horizon & planned interim analysis
• Appropriateness of pre-specified analyses
• Interpretation of the results
• Identification of issues related to data access
• Identification of strengths & limitations of the registry
4) Issues during the publication of the results
5) Other issues
6) Assessment of learnings
• General learning topics
• Value of the registry organization
◦ Inclusion of patients in the SAB and in the WC
◦ Inclusion of clinicians in the SAB and in the WC
◦ Inclusion of members from the pharmaceutical industry in the SAB and
in the WC
• Pitfalls and learning opportunities emerged from the integration of
research projects within the TOSCA registry
• Pitfalls and learning opportunities emerged from the integration of a
Votubia® PASS within the TOSCA registry
7) Additional comments
SAB, Scientific Advisory Board; WC, Working Committee; TOSCA, TuberOus SClerosis
registry to increase disease Awareness; PASS, post approval safety study.
rates per type of participant who filled the questionnaire in
(hereafter referred to as “respondents”) were 64.3% (18/28) for
members of the SAB including Novartis representatives,
12.3% (20/162) for PIs not included in the SAB and
4.7% (15/321) for other Novartis employees not included
in the SAB.
The overall rate of completion of the questionnaire (i.e.,
answered questions/total questions) was 88% for closed questions
(of the amount of missing data per question was 12% on average,
range 2–30%); the rates of missing data according to the type of
respondent were 4% for members of the SAB, 4% for PIs and 7%
for other Novartis employees.
Identification of Issues
A summary of all the issues reported by the survey respondents
in relation to TOSCA is shown in Figure 1. This figure
represents the main stages of the TOSCA registry (registry
planning, operation, data analysis, publication, and other) and
the issues encountered by the respondents in each of these
stages. Percentages in brackets are related to the proportion of
respondents who reported each issue. Questions from the survey
which were not rated as an issue by any of the respondents were
not included in Figure 1. These non-issue questionsmainly relate
to the identification of clinicians to lead the research projects
or to delays in the development of the registry due to patient
identification. All respondents also agreed that no issues arose
neither on the grade of involvement of WC members in the
protocol and related documents, nor in the documentation of
protocol amendments, nor whether the information about these
amendments was provided in a timely manner to respondents.
Finally, no issues were reported regarding registry oversight or
the adverse event collection/reporting processes.
Registry Planning
The limited duration of the registry (up to 5 years) was
considered the most common issue amongst the survey
respondents (38%). There was a consensus amongst those
answering the questionnaire on the appropriateness of having
a long-term registry and some respondents stated that a
longer follow-up would have been good in order to capture
the impact of the disease in a more realistic way; however,
constraints, such as budget limitations, were impactful leading
to substantial amounts of missing data from follow-up 3.
Respondents considered the registry too ambitious in terms
of recruitment, duration or compliance and its long-term
sustainability unrealistic. Conversely, timeline delays, risk, and
project plan problems and issues when defining SAB-WC
members were the lowest-rated complications associated with
registry planning.
Operation of the Registry
Missing data were the main complication stated by respondents
in relation to the operational domain of the registry (32%)
(Figure 1). Variables with the most data missing were related
to TSC-Associated Neuropsychiatric Disorders (TAND)—
for reasons such as the lack of knowledge of these TSC
manifestations by the physicians—or patient/caregiver reported
outcomes, whereas those with fewer missing data were associated
to physical signs and symptoms of the patients. A low proportion
of respondents stated issues related to resources and costs and
there were mainly related to budget limitations, especially toward
the research projects.
Data Analysis
The effect of bias on the validity of the results was considered
as the main issue related to data analysis by the respondents
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FIGURE 1 | Typology and Weight of Issues derived from the Different Stages within the TOSCA Registry. CRF, case report form; FAIR, Findable, Accessible,
Interoperable and Reusable (data); MD, missing data; PCRO, patient-caregiver reported outcomes; PP, project plan; RP, research project; SAB, Scientific Advisory
Board; WC, Working Committee.
(25%), together with the incorrect treatment of missing data
(stated by 23% of the respondents). More than half of the
respondents (51%) agreed on the presence of some type of bias,
either selection bias (e.g., unclear inclusion-exclusion criteria or
registry population as a non-random selection from the target
population), information bias (e.g., selective recall, inconsistent
data collection, or wrong-inexact data recording) and/or
measurement bias (e.g., faulty-inaccurate measurements or
misclassification of outcomes). The involvement of statisticians
throughout the whole project from its conception, budget
extensions or further monitoring during data collection were
considered as potential solutions to these issues by the
respondents. Issues related to interim analyses and missing data
handling were amongst the least reported by the respondents
(4% of the respondents each issue) (Figure 1) in this section and
mainly related to the desire of making these analyses longer and
the missing data present in the final follow-ups (follow-up 4 and
follow-up 5).
Publication of Results and Other Issues
Regarding publication of the results and other issues, the
lack of contribution to the TOSCA registry and the lack of
participation in manuscripts were the issues most rated by the
respondents in the survey (21 and 19%, respectively), whereas
questions related to data requirements between countries and
final approval of publications were considered the less important
complications related to the registry (2% of the respondents
each issue). Overall, respondents felt that no authorship conflicts
(e.g., issues related to the inclusion of all authors and/or the
order in which some authors appeared in publications) happened
during the publication process (<10% of respondents stated this
type of issue).
Assessment of Lessons Learnt From
TOSCA Registry
Table 2 shows contributions of the TOSCA registry to the field
of TSC and the rate of agreement of the respondents with
these contributions. These contributions were classified into the
ones finally accomplished by TOSCA registry and those not
accomplished, either because it was not achieved even though it
was intended or because it was not intended (Table 2). Overall,
the rates of completeness were high in this section of the
questionnaire, with an average rate of missing data of 5% per
question (range 2–15%) mainly due to the fact that they did not
remember the data or did not have access to it.
More than 80% of the survey respondents perceived that
TOSCA improved the knowledge on the natural history and
manifestations of TSC, increased the awareness of the disease
and helped to identify information relevant to clinical research.
Thus, overall there was a convergence that the TOSCA registry
positively contributed to make progress into the knowledge
of TSC, although one respondent considered this progress as
small given the cost and time spent in the registry. The lowest
consensus was reached on the items “the registry contributed
Frontiers in Neurology | www.frontiersin.org 5 November 2019 | Volume 10 | Article 1182
Marques et al. TOSCA Lessons for Registry Development
TABLE 2 | Assessment of lessons learnt derived from the TOSCA registry (N = 53).
TOSCA registry contributions Yes No, but it was intended No, but it was not intended Missing N/A
Improvement of knowledge on the natural
history of TSC and its manifestations
47 (89%) 3 (6%) 0 (0%) 1 (2%) 2 (4%)
Increase disease awareness 46 (87%) 2 (4%) 1 (2%) 1 (2%) 3 (6%)
Identification of useful information for the
development of clinical research in TSC
44 (83%) 2 (4%) 1 (2%) 3 (6%) 3 (6%)
Trigger research questions/developing
hypothesis for new research in TSC
41 (77%) 2 (4%) 4 (8%) 3 (6%) 3 (6%)
Improvement of epidemiological knowledge of
TSC
40 (75%) 2 (4%) 7 (13%) 1 (2%) 3 (6%)
Foster the communication between TSC
experts and Novartis
40 (75%) 3 (6%) 4 (8%) 3 (6%) 2 (4%)
Improvement of knowledge on the clinical
management of the disease in different
countries
38 (72%) 3 (6%) 7 (13%) 1 (2%) 4 (8%)
Provision of data on quality of life 38 (72%) 3 (6%) 8 (15%) 2 (4%) 2 (4%)
Identification of useful information for the
development of studies involving large/diverse
geographic areas
38 (72%) 3 (6%) 6 (11%) 2 (4%) 3 (6%)
Foster the communication between TSC
experts
38 (72%) 3 (6%) 7 (13%) 3 (6%) 2 (4%)
Provision of data on the effectiveness &
efficiency of interventions in the real world
37 (70%) 7 (13%) 5 (9%) 2 (4%) 2 (4%)
Improvement of clinical practice 37 (70%) 4 (8%) 7 (13%) 2 (4%) 3 (6%)
Quantification of the use of resources and the
burden of the disease
37 (70%) 7 (13%) 3 (6%) 2 (4%) 4 (8%)
Identification of centers/physicians treating
patients with TSC
35 (66%) 5 (9%) 7 (13%) 4 (8%) 2 (4%)
Identification of useful information for the
development of studies in pediatric patients
34 (64%) 3 (6%) 10 (19%) 2 (4%) 3 (6%)
Foster the communication between TSC
experts and patients
34 (64%) 4 (8%) 7 (13%) 4 (8%) 3 (6%)
Assessment of the agreement between clinical
practice and guidelines
33 (62%) 7 (13%) 9 (17%) 2 (4%) 2 (4%)
Provision of data on the safety of the
interventions in patients with TSC in the real
world
31 (58%) 7 (13%) 10 (19%) 3 (6%) 2 (4%)
Improvement of health care planning &
resource allocation
31 (58%) 9 (17%) 8 (15%) 2 (4%) 3 (6%)
Development of new clinical practice guidelines 30 (57%) 8 (15%) 9 (17%) 3 (6%) 3 (6%)
Identification of patients with TSC that might
benefit from certain interventions or might be
included in future clinical trials
30 (57%) 8 (15%) 9 (17%) 3 (6%) 3 (6%)
Identification of useful information for the
development of clinical research in other rare
diseases
28 (53%) 6 (11%) 10 (19%) 4 (8%) 4 (8%)
Foster the communication between TSC
patients and Novartis
24 (45%) 7 (13%) 12 (23%) 6 (11%) 3 (6%)
Facilitation of market access for Votubia® 23 (43%) 6 (11%) 10 (19%) 8 (15%) 4 (8%)
TOSCA, TuberOus SClerosis registry to increase disease Awareness; TSC, Tuberous Sclerosis Complex.
to facilitate market access for Votubia R©” and “the registry
contributed to foster the communication between TSC patients
and Novartis”, agreed by <50% of the respondents.
The items where TOSCA made no contribution to the fields
of rare diseases registries or TSC were classified in those where
the registry was not meant to contribute and those where the
contributionwas intended but not accomplished (Table 2). Fewer
than 20% of respondents stated items where the contribution
was intended but not accomplished, mainly in improving
healthcare planning and resource allocation (17%) or developing
new guidelines (15%). The items from which the contribution
was not accomplished but also not intended were mainly
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related to foster the communication between TSC patients and
Novartis (23%).
Most respondents considered the inclusion of different groups
(TSC experts [reported by 84%], the pharmaceutical industry
[reported by 75%] and patient representatives [reported by
59%]) in the SAB and the WC as either important or very
important, despite some respondents were concerned that
including patient representatives would create issues, such as
ethical issues (reported by 6%) or confidentiality issues (reported
by 6%). Overall, more than 75% of the respondents considered
the inclusion of patient representatives to be good in facilitating
communication—about the registry’s purpose and value to
patient advocacy groups—and to furthermore increase public
awareness of the disease. Seventeen percent of the respondents
also stated that they would have increased the number of
patient representatives in the SAB/WC, especially if they had
medical background.
There was a clear convergence regarding the importance of
including TSC experts in the SAB and the WC, especially to
provide interpretation of results, to propose the collection of
variables and analyses of medical interest and to improve the
quality of publications (more than 90% of respondents rated the
inclusion of TSC experts as relevant or very relevant for these
items). However, respondents considered the overall number
of TSC experts to be too high in both in the WC and SAB.
There was also agreement about the importance of including
members of the pharmaceutical industry in the SAB and the
WC, especially to provide technical, and/or financial support
in the dissemination and publication of the results (rated as
important or very important by more than 80% of respondents).
However, the inclusion of different pharmaceutical companies
as well as members with more specific skills (e.g., statistics,
medical, operational, datamanagement) was felt necessary by few
respondents (9 and 2%, respectively).
Pitfalls and Lessons Learnt From the Integration of
Research Projects Within the TOSCA Registry
More than half of the respondents (57%) considered appropriate
to include research projects within the structure of the TOSCA
registry. Further benefits derived from the projects were the
extensive data collection and its multidisciplinary nature, which
would have allowed a deep analysis of specific areas of TSC
resulting in better knowledge of the disease, and furthermore the
procurement of patient reported outcomes, such as burden of
illness or quality of life.
On the other hand, respondents also stated that research
projects were complex, burdensome and should have been
considered at the registry planning stage (as they were included
as study protocol amendments). The absence of publications and
statistical plans together with the lack of budget (for aspects such
edit checks on collected data or PI reimbursement for data entry)
and patient retention were other pitfalls stated in the survey.
On average, 38% of respondents considered that separating
the core from the research projects was a good idea; conversely,
17% of the respondents on average stated that this separation
caused delays and agreed that both the core and the research
projects should have been done simultaneously.
No consensus was reached regarding the efficiency in resource
management for the research projects (28% of respondents
considered the management efficient, whereas 23% thought it
was not).
Regarding the contents of the core and the research projects,
there were mixed opinions on whether some variables in the
core registry should have been included in the research projects,
and vice versa (21% said “yes” vs. 23% said “no,” 43% said
“N/A,” 13% were missing). Regarding the amount of missing
data, there was also an absence of consensus regarding whether
the proportion of missing data was similar between the core
and the research projects; missing data appeared to be reported
similar between the core and the research projects by 18% of the
respondents who provided a valid answer (e.g., yes, no or N/A),
while considered different by 25%. The opinions reflected in the
answers on whether the number of respondents in the research
projects was sufficient to answer questions of clinical relevance
were heterogeneous (19% said “yes” vs. 26% said “no”; 38% said
“N/A”, 15% were missing). More consensus was obtained on
the representativeness of the results, as 38% of the respondents
providing a valid response stated that results from the research
projects could be extrapolated to all the respondents in the core
registry, and 43% stated that results from the research projects
would be representative of real world.
Finally, more respondents agreed that research projects
provided striking or relevant results (17% said “yes” vs. 13% said
“no,” 51% “N/A”, 19% were missing) while there was uncertainty
on whether new projects emerged from the research projects (13
vs. 11% said “yes” and “no,” respectively; 58% reported “N/A”,
17% were missing). Of those who stated that the research projects
provided relevant findings, these were related to the impact
on renal angiomyolipoma (rAML), the effects of subependymal
giant cell astrocytoma (SEGA) in adults, the results obtained in
TAND and aspects related to quality of life. Appropriateness in
the dissemination of results was uncertain (19% said “yes”, 19%
said “no”, 42% said “N/A”, 21% were missing).
Pitfalls and Lessons Learnt From the Integration
Everolimus, Votubia® PASS (Post Authorization
Safety Study) Within the TOSCA Registry
Some questions in the survey were related to the PASS study,
which was embedded in the TOSCA registry to evaluate the
long-term safety profile of everolimus (commercially known as
Votubia R©) an orphan drug directed to treat SEGA, rAML and
seizures that did not respond to other treatments. Almost half
of the respondents (43%) considered appropriate to integrate the
PASS study within the TOSCA registry, mainly due to efficiency
gains such as better surveillance, retention, recruitment, and
long-term effects of adverse events. However, some pitfalls also
emerged from this integration, as the extra workload imposed
by PASS within TOSCA design, the characterization of PASS as a
sub-study of TOSCA and the important differences between both
studies (e.g., administrative, reporting, regulatory requirements).
Approximately 30% (range 26–34%) of respondents agreed on
the convenience of separating the elaboration, data collection,
and approval of both the PASS and TOSCA, and 32% of the
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respondents considered that there was a good management of
time and resources in PASS.
Conversely to what happened with the research projects, more
respondents considered that there were no variables in PASS that
should have been collected in the core registry or vice versa (9
vs. 19%, on average). Twenty-one percent of the respondents
considered data quality and completeness was worse in the
TOSCA registry than in the PASS. There were discrepancies
between respondents regarding the number of patients in PASS,
with 13% of respondents thinking they were sufficient vs. 9%
who considered the sample unrepresentative (60% said “N/A”,
17% were missing). A bigger proportion of the respondents
considered the results in PASS representative of the whole
TOSCA population (17%) and translatable into real world (25%)
that those who did not (8 and 2%, respectively). Importantly,
none of the respondents perceived that new projects emerged
from the PASS study, although there was an important degree of
uncertainty surrounding this item (19% said “no,” 62% reported
“N/A,” 19% were missing).
Regarding the dissemination of results, respondents had
mixed opinions (11% said “yes”, 8% said “no”, 62% reported
“N/A”, 19% were missing). No consensus was reached regarding
the potential benefit on the TOSCA registry derived by the
interaction of health authorities during the PASS, again with
important levels of uncertainty (8% said “yes”, 8% said “no”, 68%
wrote “N/A”, 17% were missing).
DISCUSSION
The analyses performed here identified the main issues that arose
during TOSCA registry from its inception to the publication of
the results, and the take-home messages and lessons that could
be relevant to the design and development of future registries in
rare and complex diseases.
All the respondents agreed that one of the most positive
aspects of the TOSCA registry was the involvement of a
range of stakeholders (including TSC experts, members from
industry, and patients). By involving people with different
perspectives and profiles, the study analyzed variables that were
of interest to physicians, to the pharmaceutical industry, and
most importantly, to patients.
There is a growing emphasis on patient-focused registries (6)
and, in this particular case, patients’ representative in the SAB
were considered a key element to facilitate communication of
the results to advocacy groups, and to increase public awareness
on the disease. Other successful examples of registries with an
active participation of patients in its design, governance and/or
operation are the ImproveCareNow network for inflammatory
bowel disease in the United States (7), the ParkinsonNet
Approach in the Netherlands (8), and the TREAT-NMD
European network for neuromuscular disorders (9).
In the TOSCA registry, no issues were reported regarding
registry oversight, adverse event collection/reporting processes
(only related to the PASS sub-study), or project management,
which means that these aspects worked particularly well. The use
of standard operational procedures may have helped to prevent
this type of issues and is highly advised for the development of
future registries.
Another aspect that was rated positively was the high
recruitment in the core project. The recruitment strategies varied
among the enrolling countries and included phone contacts,
proposal of participation in scheduled visits, exploitation of
local patient databases, targeted mailing and newsletters to the
investigators, virtual investigator meetings and the contacts with
local patients’ associations and family groups.
By contrast, patient retention was poor in TOSCA registry;
after 3 years follow up, some sites stopped reporting data in a
constant manner and a high number of patients discontinued
(93.5%). Patient discontinuation is a common issue in all the
registries. Therefore, strategies to reduce losses to follow-up
are urgently needed, especially when taking into account that
approximately a third of the respondents answered that they
would have preferred the TOSCA registry to have a longer
duration or even to be permanent.
The contrast between the low retention rates and the high
expectations highlights the need for realistic goals when setting
up a registry, but also the need for continuous motivation,
adequate budget, and close oversight for registries that are
expected to last longer than one or 2 years. Unfortunately, long-
term sustainability is an important issue for most registries (1).
Issues related to missing data collection were among the
most common difficulties during the operation of the registry
and during data analysis, especially in the last follow-up visits.
According to one of the respondents, carrying out a pilot study
would have been useful to make sure questions were formulated
in the most optimal way, and to reduce the amount of missing
data. Other strategies related to missing data reduction or
handling are to detail mechanisms to identify and collect missing
data in the protocol, to distinguish between nice-to-have, and
essential data (as in TOSCA study management document like
the CRF manual and of monitoring plan) and to describe the
handling of missing data in the statistical analysis plan (also part
of TOSCA study management documents) (1).
Issues related to language translations were not observed
in the TOSCA registry, which can be considered a success in
a project involving 31 countries. Within the TOSCA registry,
the impact of translation issues was minimized by several
actions, such as the study oversight and site support provided
in local languages including the discussion of the protocol
and the electronic case report forms (eCRFs) requirements.
In spite of this, one of the respondents mentioned that in
any future multinational project, agreeing, and defining each
term or concept with representatives from each country and
language would be important to avoid any issue related to
a mistranslation. These solutions might be useful for future
multinational registries.
During data analysis, the most important issues were
related to biases. Due to its observational nature, registries
are prone to many biases. In this case, several respondents
concluded that, due to selection bias toward patients with
severe manifestations recruited in large hospitals and reference
centers, the burden of the disease might have been overestimated.
Another reason for selection bias was the overrepresentation
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of pediatric neurologists. Despite of the biases, the TOSCA
registry provided relevant information about the presence of
clinical manifestations on TSC patients such epilepsy that was
useful from an epidemiological point of view. Besides, the eCRF
included some specific questions for some specialties that could
not be answered properly by all the participants; therefore,
data collection for some specialties such as dermatology or
ophthalmology was not completely reliable. Future studies
should ensure that the sample is sufficiently homogeneous
and representative of the population to be analyzed, that the
investigators are a representative sample of the physicians
treating that condition, and that all the variables can be properly
assessed by the investigators involved in the study. Reducing bias
therefore requires the participation of statisticians when planning
the project, a careful site and PI selection across countries
and also an increased and continuous support at site level to
understand study requirements and eCRF questions. This issue
was always specified in the different results and publications of
the TOSCA registry, where it was emphasized that this is not an
epidemiological study, but a very large cohort study.
Apart from potential biases andmissing data issues, there were
difficulties related to data access. In spite of the existence of a
definition of the terms for data access, one TSC expert believed
that the data access rights favored too much the sponsor and
others thought that they were not clear enough. Therefore, more
efforts are required to involve all the stakeholders in the definition
of data access terms. In this respect, a discussion paper elaborated
by the EMA Cross-Committee Task Force on Patient Registries
goes even further, and acknowledges that “clarity is needed
regarding data ownership, including patients’ wishes regarding
the use of their data” (1).
Issues during the publication of data from other registries
have not been previously analyzed. Authorship conflicts were
reported by 9% of the respondents. The most frequent issues
were related to the poor involvement of some authors in
the manuscripts or the lack of acknowledgment for all the
contributors. This highlights the need for authorship criteria
based on real contribution instead of pre-signed agreements.
Another conclusion resulting from analyzing the deviations
between the planned and the expected journals for the
publication is that setting unrealistic target journals might be
an important cause for delays during the publication process.
The difficulties related to publishing results from yearly follow-
ups should also be taken into account when devising a
publication plan.
According to most respondents, it was positive to carry
out research projects besides the TOSCA registry because they
allowed to carry out detailed analyses of specific manifestations
in patients with TSC or provided additional information on
the burden of the disease. However, due to insufficient funding
and to the lack of specific statistical and publication plans,
the validity and dissemination of the results from the research
projects were scarce. In addition, most respondents considered
that the research projects were not well-handled and that the
implication from the investigators was not sufficient. This might
be seen as a lost opportunity, but also as a need for better
planning for studies emerging from registries, and highlights
the need to include detailed budget planning within all project
proposals. Interestingly, the EMA provided very clear guidance
on this matter stating the importance of differentiating between
registries (including their periodic analyses) and registry studies.
In line, protocols are meant to be completely separate, meaning
the addition of research projects as amendments are not in line
with the Good Registry Practice and should be considered as
almost separate studies with their own budget, management,
monitoring, etc. (1).
Conversely, most respondents considered data quality and
completeness were worse in the TOSCA registry than in the
PASS.While it is true that the aims of a PASS study are completely
different from those in the TOSCA registry, a better integration
of the TOSCA registry and the PASS could have been exploited to
increase the quality of the TOSCA registry.
The analysis of the lessons from TOSCAmight also have some
limitations. First, it is only based on one single registry experience
in patients with a single disease. However, most of the issues are
applicable to registries in other diseases. The second limitation
is associated to the low number of TSC patients’ representatives
who were able to fill this questionnaire. This might be due to the
low percentage of patient representatives in the SAB. Thirdly,
a major limitation was the high percentage of the SAB in the
respondents’ group. Some reasons for the low response rates
of the PIs and Novartis employees could be the perception on
the burdensomeness of the questionnaire, the lack of economic
compensation for the participants, a decreasing interest in the
study or a lack of belief in the interest of such questionnaire. In
future studies, a pilot of the questionnaire should be performed in
a small sample of the population before being distributed further
in order to test the validity and reliability of the questionnaire and
to improve response rates.
Finally, the questionnaire was designed and sent 1 year after
the completion of the registry, and this may have resulted in
recall biases. In any case, we believe that by performing the
analysis retrospectively, we could obtain a complete view on the
difficulties arisen throughout the project.
In conclusion, this analysis has contributed to foresee
and prevent issues in the design and development of future
multinational registries in rare diseases. Careful planning,
adequate monitoring and sufficient budget allocation are key
elements for the success of registries. By contrast, there is a
need to improve data quality, to reduce biases, to avoid access-
related issues, and to ensure patient retention and long-term
sustainability. Finally, this analysis also shows that registries are
a powerful tool to increase disease awareness, and to produce
a real-world view of clinical practice, but they have many
limitations too. When designing and carrying out a registry,
keeping a balance between ambition, pragmatism, and costs is a
difficult task.
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